Interview with Ulrich Behrendt, President, VBU
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Address: Theodor-Heuss-Allee 25 D – 60486 Frankfurt am Main,Germany
Tel: 069 / 75 64- 124
VBU – Association of German Biotech Companies was founded in October 1996 on the initiative of 55 biotech companies. VBU now has over 210 corporate members, making it the largest and oldest industrial biotechnology association in Germany.Since its foundation VBU has devoted itself to the promotion of science and technology and the transfer of research findings into innovations. Furthermore VBU works in close collaboration with other national and international organisations from the areas of biotechnology, pharma, and knowledge and technology transfer.VBU is part of DECHEMA e.V. which was founded in 1926. Today DECHEMA has over 5,000 personal and sustaining members from science and industry.DECHEMA pools the know-how of experts, provides strong networks for research and development, is a platform for expert information, communication, and practice-oriented exchange of ideas and experience. DECHEMA is at the interface between science, industry, regulatory bodies and the public.
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
See our Cookie Privacy Policy Here
